Quoin Pharmaceuticals (QNRX) Competitors $6.66 -0.04 (-0.60%) Closing price 08/1/2025 03:56 PM EasternExtended Trading$6.66 0.00 (0.00%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock QNRX vs. NXL, OSRH, NXGL, IINN, BDMD, MHUA, XAIR, DHAI, INBS, and LYRAShould you be buying Quoin Pharmaceuticals stock or one of its competitors? The main competitors of Quoin Pharmaceuticals include Nexalin Technology (NXL), OSR (OSRH), NexGel (NXGL), Inspira Technologies OXY B.H.N. (IINN), Baird Medical Investment (BDMD), Meihua International Medical Technologies (MHUA), Beyond Air (XAIR), DIH Holding US (DHAI), Intelligent Bio Solutions (INBS), and Lyra Therapeutics (LYRA). These companies are all part of the "medical equipment" industry. Quoin Pharmaceuticals vs. Its Competitors Nexalin Technology OSR NexGel Inspira Technologies OXY B.H.N. Baird Medical Investment Meihua International Medical Technologies Beyond Air DIH Holding US Intelligent Bio Solutions Lyra Therapeutics Nexalin Technology (NASDAQ:NXL) and Quoin Pharmaceuticals (NASDAQ:QNRX) are both small-cap medical equipment companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, media sentiment, profitability and analyst recommendations. Do institutionals and insiders believe in NXL or QNRX? 0.6% of Nexalin Technology shares are held by institutional investors. Comparatively, 8.6% of Quoin Pharmaceuticals shares are held by institutional investors. 25.3% of Nexalin Technology shares are held by company insiders. Comparatively, 13.5% of Quoin Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has higher valuation & earnings, NXL or QNRX? Nexalin Technology has higher revenue and earnings than Quoin Pharmaceuticals. Nexalin Technology is trading at a lower price-to-earnings ratio than Quoin Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNexalin Technology$131.07K129.61-$7.61M-$0.83-1.19Quoin PharmaceuticalsN/AN/A-$8.96M-$48.81-0.14 Do analysts recommend NXL or QNRX? Nexalin Technology presently has a consensus price target of $5.00, suggesting a potential upside of 405.61%. Given Nexalin Technology's stronger consensus rating and higher possible upside, research analysts plainly believe Nexalin Technology is more favorable than Quoin Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nexalin Technology 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Quoin Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is NXL or QNRX more profitable? Quoin Pharmaceuticals has a net margin of 0.00% compared to Nexalin Technology's net margin of -6,529.77%. Quoin Pharmaceuticals' return on equity of -148.97% beat Nexalin Technology's return on equity.Company Net Margins Return on Equity Return on Assets Nexalin Technology-6,529.77% -277.92% -245.37% Quoin Pharmaceuticals N/A -148.97%-77.23% Does the media refer more to NXL or QNRX? In the previous week, Quoin Pharmaceuticals had 2 more articles in the media than Nexalin Technology. MarketBeat recorded 4 mentions for Quoin Pharmaceuticals and 2 mentions for Nexalin Technology. Quoin Pharmaceuticals' average media sentiment score of 0.37 beat Nexalin Technology's score of 0.00 indicating that Quoin Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nexalin Technology 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Quoin Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility and risk, NXL or QNRX? Nexalin Technology has a beta of 3.7, suggesting that its stock price is 270% more volatile than the S&P 500. Comparatively, Quoin Pharmaceuticals has a beta of 1.44, suggesting that its stock price is 44% more volatile than the S&P 500. SummaryNexalin Technology beats Quoin Pharmaceuticals on 8 of the 15 factors compared between the two stocks. Get Quoin Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for QNRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding QNRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart QNRX vs. The Competition Export to ExcelMetricQuoin PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.94M$2.47B$5.47B$9.53BDividend YieldN/A1.81%4.74%4.08%P/E Ratio-0.148.9728.6723.80Price / SalesN/A639.64422.2688.08Price / CashN/A157.7635.4557.96Price / Book0.194.838.275.55Net Income-$8.96M$31.62M$3.24B$259.03M7 Day Performance-19.86%-5.28%-3.63%-4.56%1 Month Performance-27.53%4.38%4.40%4.49%1 Year Performance-67.72%-2.49%25.97%18.05% Quoin Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)QNRXQuoin Pharmaceuticals1.7019 of 5 stars$6.66-0.6%N/A-67.0%$3.94MN/A-0.144News CoveragePositive NewsNXLNexalin Technology2.1895 of 5 stars$1.06-6.3%$5.00+372.1%-13.3%$18.19M$170K-1.283News CoveragePositive NewsOSRHOSRN/A$0.92-2.5%N/AN/A$17.74MN/A0.00N/ANews CoverageNXGLNexGel0.5341 of 5 stars$2.30+0.9%N/A-12.9%$17.60M$8.69M-5.1110News CoverageGap DownHigh Trading VolumeIINNInspira Technologies OXY B.H.N.1.632 of 5 stars$1.26-6.0%$2.00+58.7%+10.8%$15.90MN/A0.0020BDMDBaird Medical InvestmentN/A$2.03-3.3%N/AN/A$13.36MN/A0.00N/AGap DownMHUAMeihua International Medical Technologies1.6085 of 5 stars$0.40+3.2%N/A-59.9%$12.89M$96.90M0.00620XAIRBeyond Air3.6802 of 5 stars$2.97-7.2%$23.67+696.9%-74.0%$12.83M$3.70M-0.1970Short Interest ↑DHAIDIH Holding US0.5848 of 5 stars$0.25-7.0%N/A-91.5%$11.88M$64.47M-0.84N/ANews CoverageINBSIntelligent Bio Solutions0.5622 of 5 stars$1.55+1.3%N/A+9.7%$10.71M$3.11M0.0010LYRALyra Therapeutics2.9764 of 5 stars$7.53-3.5%$100.00+1,228.9%-57.0%$9.97M$1.19M-0.1250Positive News Related Companies and Tools Related Companies NXL Competitors OSRH Competitors NXGL Competitors IINN Competitors BDMD Competitors MHUA Competitors XAIR Competitors DHAI Competitors INBS Competitors LYRA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:QNRX) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quoin Pharmaceuticals, Ltd. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Quoin Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
